EUCTR2010-020348-36-GB进行中（未招募）不适用
Randomized double-blind Phase III trial of FOLF(HA)iri vs FOLFIRI forsecond or third line therapy in irinotecan-naïve patients with metastaticcolorectal cancer - HA-Irinotecan Phase III trial ACO-002
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 640
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1) Metastatic colorectal cancer with disease progression after first or second line
- •chemotherapy (adjuvant chemotherapy is considered first line chemotherapy if relapse occurs within 6 months of the end of the adjuvant chemotherapy).
- •See Section 4.2 of the study protocol for prior chemotherapy requirements and for required documentation of disease progression.
- •2) Irinotecan naïve, i.e. no prior irinotecan.
- •3) ECOG performance status of 0 or 1.
- •4) Measurable disease, i.e. at least one measurable metastatic lesion (=1cm on spiral CT or MRI).
- •5) Histological proof of colorectal cancer (from either primary or metastatic lesion).
- •6) 18 years of age and older.
- •7) Adequately recovered from and at least 4 weeks after recent surgery or chemotherapy to randomization (to the start of screening defined as the date of the first screening procedure; screening includes CT or MRI scans as defined below).
- •8) At least 4 weeks after treatment with a biologic monotherapy from last dose to randomization.
- •9) Women of child-bearing potential (WOCBP) and male partners of WOCBP must agree to use adequate contraception. WOCBP and male partners of WOCBP must agree to use adequate contraception prior to study entry, throughout the study and for a period of four weeks after cessation of protocol therapy. WOCBP include women who have experienced menarche and who have not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or are not postmenopausal (defined as amenorrhoea > 12 consecutive months). Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or who are practicing abstinence or whose partner is sterile (eg., vasectomized) should be considered to be of child-bearing potential.
- •10) Patient consent obtained and signed according to local Institutional and/or University Human Experimentation Committee requirements and/or a central Institutional Review Board (IRB).
- •11) CT or MRI scan of chest/abdomen/pelvis with other scans as necessary to document all sites of disease, done within 21 days prior to randomization. Contrast enhancement should be used if no contraindication. The same imaging method should be used for the patient throughout the entire study (e.g. if a patient starts with CT scans all subsequent imaging should be with CT scans).
- •12) Hematology done within 14 days prior to randomization:
- •a. Absolute Neutrophil Count (ANC) >1.5 x 10(9)/L
- •b. Platelets > 100 x 10(9)/L
- •c. Hemoglobin = 100g/L (transfusions may be used to raise hemoglobin to =100g/L,
- •but there must be no evidence of active bleeding)
- •13) Chemistry done within 14 days prior to randomization:
- •a. AST = 2.5 X ULN (= 5 X ULN if elevation thought to be related to hepatic
- •metastatic disease)
- •b. Alkaline phosphatase < 5 x ULN
- •c. Serum creatinine < 1.5 x ULN
- •d. Total bilirubin = 2.0 mg/dl. (<34.2 µmol/L equivalent)
- •e. Negative serum or urine pregnancy test if a WOCBP.
- •14) Patients must be accessible for treatment and follow-up, including complete
- •documentation of the treatment, toxicity, and follow-up.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 464
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 176
排除标准
- •1) History of other malignancies, except adequately treated non-melanoma skin cancer, curatively treated in-situ cancer of the cervix, or other solid tumors curatively treated with no evidence of disease for > 5 years.
- •2) Locally advanced or recurrent disease only, i.e. patients may have locally advanced or recurrent disease, but must also have measurable, metastatic disease.
- •3) Unsuitability for irinotecan including known Gilbert’s syndrome, active inflammatory
- •bowel disease or chronic diarrhea = grade 2.
- •4) Abdominal or pelvic radiation therapy (including treatment with SIR-Spheres/Sirtex) within the last 12 months (i.e. the last day of prior radiation therapy must be 12 months prior to the start of screening; defined as the date of the first screening procedure).
- •5) Women who are pregnant or breastfeeding.
- •6) Any condition (e.g., psychological, geographical) that would render the protocol
- •treatment dangerous, impair the ability of the patient to receive protocol therapy or that would impair compliance with the protocol.
- •7) Significant cardiac disease, defined as myocardial infarction within 3 months prior to randomization, congestive heart failure classified by the New York Heart Association as Class III or IV (Appendix A.9), uncontrolled cardiac arrhythmias, poorly controlled or unstable angina, or electrocardiographic evidence of acute ischemia.
- •8) Untreated or symptomatic brain or central nervous system (CNS) metastases (head CT or MRI is required only in the presence of neurological symptoms or signs consistent with cerebral metastases).
- •9) Pleural effusion or ascites requiring therapeutic thoracocentesis or paracentesis and pleural effusion or ascites described in the radiological summaries as significant.
- •10) Current partial or complete bowel obstruction.
- •11) Concomitant active infection.
- •12) Enrolled in any other investigational trial, unless treatment in that trial has been discontinued at least 30 days prior to start of screening, defined as the date of the first screening procedure, and that treatment was fully compliant with the ACO-002 entry criteria. Patients who progressed in a previous trial and are still in follow up - will require case by case discussion with the Medical Monitor and Alchemia.
研究者
相似试验
进行中（未招募）
不适用
Phase III clinical trial of FOLF(HA)iri vs FOLFIRI forsecond or third line therapy in irinotecan-naïve patients with metastaticcolorectal cancerMetastatic colorectal cancer (mCRC)MedDRA version: 17.1Level: LLTClassification code 10052362Term: Metastatic colorectal cancerSystem Organ Class: 100000004864EUCTR2010-020348-36-BGAlchemia Oncology Pty Ltd390
进行中（未招募）
3 期
Phase 3, randomized, double-blind study of the efficacy of TM5614 in combination with tyrosine kinase inhibitors in chronic phase chronic myelogenous leukemia patientsChronic myelogenous leukemia in chronic phaseCMLD015464JPRN-jRCT2031220084Harigae Hideo60
进行中（未招募）
不适用
Phase II trial to evaluate the combination of FOLFOX6 + Bevacizumab in initially unresectable liver metastases from colorectal cancerMETASTHATIC COLON-RECTUM AND KIDNEY CANCERMedDRA version: 9.1Level: LLTClassification code 10055114Term: Colon cancer metastaticEUCTR2005-002269-35-ITAZIENDA OSPEDALIERA POLICLINICO DI MODENA
Unknown
3 期
Trial of FOLF(HA)Iri Versus FOLFIRI in mCRCMetastatic Colorectal CancerNCT01290783Alchemia Oncology390
进行中（未招募）
1 期
A study to investigate weekly treatment administration of Setmelanotide compared to daily administration in patients that have a form of genetic obesity.Treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Diseases that are the result of genetic defects affecting the MC4R pathway, concerned by the trial: - Bardet-Diedl syndrome- Biallelic PPL - Heterozygotous PPL (PPL : POMC pro-opiomelanocortin, PCSK1 proprotein convertase subtilisin/kexin type1 , LEPR leptin receptor)MedDRA version: 23.0Level: PTClassification code 10084105Term: Leptin receptor deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 23.0Level: PTClassification code 10083937Term: Pro-opiomelanocortin deficiencySystem Organ Class: 10010331 - Congenital, familial and genetic disordersMedDRA version: 20.1Level: LLTClassification code 10048680Term: Bardet-Biedl syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2021-004597-65-DERhythm Pharmaceuticals, Inc.30